CP 673 (mastic)

Hazard statements (CLP)

H317

Code

Statements

H317

May cause an allergic skin reaction

SECTION 2: Hazards identification

According to Regulation (EC) No. 1272/2008 (CLP) Classification of the substance or mixture

Adverse physicochemical, human health and environmental effects

May cause an allergic skin reaction

Hazard pictograms

GHS07

Signal word

Warning

Contains

Mixture of 5-chloro-2-methylisothiazol-3(2H)-one and 2-methylisothiazol-3(2H)-one ; 2- methyl-2H-isothiazol-3-one (MIT)

Hazard statements

H317 - May cause an allergic skin reaction

Precautionary statements

P280 - Wear Protective clothing, protective gloves, eye protection. P302+P352 - IF ON SKIN Wash with plenty of soap and water. P333+P313 - If skin irritation or rash occurs Get medical advice/attention

Other hazards

This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII Contains no PBT and/or vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII Component Mixture of 5-chloro-2-methylisothiazol-3(2H)-one and 2-methylisothiazol-3(2H)-one (55965-84-9) hexaboron dizinc undecaoxide, heptahydrate (138265-88-0) 2-methyl-2H-isothiazol-3-one (MIT) (2682-20-4) This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII 1,2-Benzisothiazol-3(2H)-on (2634-33-5) This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or substance(s) are not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 % Component hexaboron dizinc undecaoxide, heptahydrate (138265-88-0) The substance is not included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 1,2-Benzisothiazol-3(2H)-on (2634-33-5) The substance is not included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 2-methyl-2H-isothiazol-3-one (MIT) (2682-20-4) The substance is not included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 Mixture of 5-chloro-2-methylisothiazol-3(2H)-one and 2-methylisothiazol-3(2H)-one (55965-84-9) The substance is not included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605

2.1 Classification of the substance or mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP] Skin sensitisation, Category 1 H317 Full text of H- and EUH-statements: see section 16 Adverse physicochemical, human health and environmental effects May cause an allergic skin reaction.